Approval · Notice of Compliance 37814 · 2026
CLOPIXOL: Notice of Compliance 37814
Issued June 30, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37814
- Date
- June 30, 2026
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLOPIXOL | Not yet assigned | — |
| CLOPIXOL ACUPHASE | Not yet assigned | — |
| CLOPIXOL DEPOT | Not yet assigned | — |
Medicinal ingredients
- ZUCLOPENTHIXOL HYDROCHLORIDE 10 MG per TAB
- ZUCLOPENTHIXOL HYDROCHLORIDE 25 MG per TAB
- ZUCLOPENTHIXOL ACETATE 50 MG per ML
- ZUCLOPENTHIXOL DECANOATE 200 MG per ML